PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.39
D/E ratio exceeding 1.5x Medical - Pharmaceuticals median of 0.00. Howard Marks would check for debt covenant compliance and refinancing risks.
-0.58
Net cash position versus Medical - Pharmaceuticals median net debt of 2.03. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
38.17
Coverage of 38.17 versus zero Medical - Pharmaceuticals median interest expense. Walter Schloss would verify if our leverage provides advantages.
0.90
Current ratio 50-75% of Medical - Pharmaceuticals median of 1.35. Martin Whitman would look for hidden assets or working capital optimization.
0.68%
Intangibles 1.25-1.5x Medical - Pharmaceuticals median of 0.50%. Martin Whitman would scrutinize acquisition strategy and impairment risks.